Petros Pharmaceuticals (PTPI) Stock Chart & Stock Price History $0.03 +0.00 (+12.73%) As of 03:59 PM Eastern Add Compare Share Share Chart Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Petros Pharmaceuticals Stock Price Performance The Petros Pharmaceuticals (PTPI) stock chart highlights key performance trends across multiple timeframes. Over the last 12 months, the stock's price has decreased 99.64%, with a year-to-date return of -99.69%. In the past month, the stock has remained steady at 0.00%, reflecting recent market activity. As of the latest close, Petros Pharmaceuticals traded at $0.03 with a market cap of $857 thousand and volume of 260,246 shares. Receive PTPI Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Petros Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address 5 Day Performance+5.08%1 Month Performance0.00%3 Month Performance-20.51%Year-To-Date Performance-99.69%1 Year Performance-99.64% PTPI Stock Chart for Monday, August, 25, 2025 PTPI Chart by TradingView Petros Pharmaceuticals Stock Price History Daily Weekly Monthly Yearly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Year 5 Year Time Frame Start Date End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization08/25/2025$0.03$0.03+12.73%$0.03$0.03751,461 shs$966,000.0008/22/2025$0.03$0.03-4.51%$0.03$0.03260,246 shs$857,000.0008/21/2025$0.03$0.03-2.37%$0.03$0.0373,527 shs$897,000.0008/20/2025$0.03$0.03$0.03$0.03749,675 shs$919,000.0008/19/2025$0.03$0.03+2.43%$0.03$0.03176,916 shs$919,000.0008/18/2025$0.03$0.03-5.88%$0.03$0.0388,245 shs$897,000.0008/15/2025$0.03$0.03-1.29%$0.03$0.03744,992 shs$953,000.0008/14/2025$0.03$0.03+6.53%$0.03$0.03225,912 shs$966,000.0008/13/2025$0.03$0.03-3.00%$0.03$0.03431,100 shs$907,000.0008/12/2025$0.03$0.03+6.76%$0.03$0.03108,839 shs$935,000.00 Get the Latest News and Ratings for PTPI and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Petros Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 08/11/2025$0.03$0.03+3.69%$0.03$0.03268,394 shs$876,000.0008/08/2025$0.03$0.03-4.24%$0.03$0.03909,932 shs$844,000.0008/07/2025$0.03$0.03+4.81%$0.03$0.03260,610 shs$882,000.0008/06/2025$0.03$0.03-8.16%$0.03$0.03811,915 shs$841,000.0008/05/2025$0.03$0.03-7.55%$0.03$0.03163,803 shs$916,000.0008/04/2025$0.03$0.03-1.85%$0.03$0.03262,626 shs$991,000.0008/01/2025$0.03$0.03+7.28%$0.03$0.03686,942 shs$1.01 million07/31/2025$0.03$0.03+9.82%$0.03$0.03862,821 shs$941,000.0007/30/2025$0.03$0.03-4.84%$0.03$0.03138,373 shs$857,000.0007/29/2025$0.03$0.03-3.99%$0.03$0.03323,602 shs$901,000.0007/28/2025$0.03$0.03-2.90%$0.03$0.03483,085 shs$938,000.0007/25/2025$0.03$0.03+3.68%$0.03$0.03361,189 shs$966,000.0007/24/2025$0.03$0.03+1.01%$0.03$0.031.40 million shs$932,000.00 Related Companies Redhill Biopharma Stock Chart Virax Biolabs Group Stock Chart CERo Therapeutics Stock Chart Qualigen Therapeutics Stock Chart BioVie Stock Chart PMGC Stock Chart Enveric Biosciences Stock Chart PowerUp Acquisition Stock Chart CNS Pharmaceuticals Stock Chart Lipella Pharmaceuticals Stock Chart Receive PTPI Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Petros Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. This page (NASDAQ:PTPI) was last updated on 8/25/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Petros Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Petros Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access